This text is a result of machine translation.
Huzhou: there is no time limit for non registered residence residents to continuously pay social security when purchasing houses in central cities
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Taier shares: the contract dispute case against Cao Linbin was accepted by the court
Central Co., Ltd. comprehensively raised the price of p-type monocrystalline silicon wafer
China Launch Startup Orienspace Raises Nearly USD 60 Mn in Series A Round
Facing the explosive demand of various satellite networks, Orienspace innovatively builds the “Gravity” series of medium-and-large-sized commercial launch vehicles, achieving the economies of scale
Yesterday 07:50 PM
Yunnan Baiyao's Revenue Rises 33%; Net Profit Falls 40% in 1Q 2021
On April 27, Yunnan Baiyao released a report for the first quarter of 2021 showing that the company's total operating revenue for the first quarter was 10.33 billion yuan, up 33.4% year-on-year; its operating profit was 880 million yuan, down 41.8% year-on-year; its net profit attributable to shareholders of the listed company was 760 million yuan.
Apr 30, 2021 02:07 AM
The Commerce Department said the shortage of chips would continue for at least six months
Yunnan Baiyao: An Oriental Mystery in the Limelight (2/2)
Tagged as ‘China’s Time-honored Brand,’ Traditional Chinese Medicine (TCM) company Yunnan Baiyao (000538:SZ) has come to an unprecedented crossroads after fulfilling the challenge of pushing TCM to the foreground.
May 19, 2020 12:30 PM
Yunnan Baiyao: An Oriental Mystery in the Limelight (1/2)
Tagged as ‘China’s Time-honored Brand,’ Traditional Chinese Medicine (TCM) company Yunnan Baiyao (000538:SZ) has come to an unprecedented crossroads after fulfilling the challenge of pushing TCM to the foreground.
May 19, 2020 12:00 PM
Exclusive Interview with Liu Di, Managing Director of Peakview Capital
Yesterday 12:51 PM